Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

X
Trial Profile

Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PFK 158 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Advanced Cancer Therapeutics
  • Most Recent Events

    • 22 Jun 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 54 to 56.
    • 22 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015.
    • 27 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top